Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 150,000 shares at $131.44 ($19.7M) on 2024-01-02, disclosed to the SEC on 2024-01-04.
Scheduled sale ($19.7M) by Chief Business Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $131.44 | 6,116 | $804K | 4.1% |
| 2 | $131.44 | 6,116 | $804K | 4.1% |
| 3 | $131.47 | 68,884 | $9.1M | 45.9% |
| 4 | $131.47 | 68,884 | $9.1M | 45.9% |
| Total | $131.47 avg | 150,000 | $19.7M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |